Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, June 13, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that Brian H. Kushner,\n MD, of the Memorial Sloan-Kettering Cancer Center in New York, will be\n making a poster presentation on Phase 1 results for perifosine in\n neuroblastoma, at the Advances in Neuroblastoma Research Conference\n which will be held June 18-21, 2012, at the Fairmount Royal York Hotel\n in Toronto.\n\n\n\n\n\nPoster #POC27: \n\n\n\"Targeting PI3K/Akt Pathway: Perifosine Monotherapy for Resistant\n Neuroblastoma in a Phase 1/1B Study\", B. Kushner, N-K.V. Cheung,\n S. Modak, O. Becher, E.M. Basu, S.S. Roberts, K. Kramer, I.J. Dunkel.\n\n \n \n\nDate and time:  \n\n\nWed., June 20, 2012, 12:30 pm - 2:30 pm + 5:30 pm - 6:30 pm (Eastern)\n\n \n \n\nVenue:   \n\n\nRoyal Canadian Ballroom, Fairmount Royal York Hotel, Toronto\n\n \n \n\nAbout Perifosine\n\n\nPerifosine is a novel, oral PI3K/Akt inhibitor compound. It is currently\n in a Phase 3 trial in multiple myeloma for which it has been granted\n orphan drug and Fast Track designations by the Food and Drug\n Administration (FDA), as well as positive Scientific Advice and orphan\n medicinal product designation from the European Medicines Agency. It\n has also been granted orphan drug designation by the FDA for\n neuroblastoma. Furthermore, perifosine is in earlier-stage development\n for other cancer indications.\n\n\nAbout Aeterna Zentaris \n\n\nAeterna Zentaris is an oncology and endocrinology drug development\n company currently investigating treatments for various unmet medical\n needs. The Company's pipeline encompasses compounds at all stages of\n development, from drug discovery through to marketed products. For more\n information please visit www.aezsinc.com.\n\n\n Investor Relations Ginette Beaudet Vallières Investor Relations Coordinator (418) 652-8525 ext. [email protected] Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. [email protected]\n","length":2621,"tagName":"div"}]

More updates from Cosciens Biopharma Inc.